
BofAS Cuts DAMAI ENT TP to HKD0.82, Reiterates Buy

I'm LongbridgeAI, I can summarize articles.
BofAS has cut the target price for DAMAI ENTfrom HKD0.86 to HKD0.82 while maintaining a Buy rating. The adjustment follows a report on the company's fiscal year 2026 results, highlighting pressure on short-term profit margins due to new business investments. Despite this, BofAS remains optimistic about long-term growth driven by live performance, content production, IP monetization, and overseas expansion, while lowering earnings forecasts for 2027-2028 by 16% to 19%. Short selling stands at $75.42M with a ratio of 26.49%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

